De novo chronic graft-versus-host disease in marrow graft recipients given methotrexate and cyclosporine: risk factors and survival.
A retrospective study was performed to determine risk factors for the development of de novo chronic graft-versus-host disease (GVHD) in patients given marrow grafts from HLA-identical sibling donors (85%), HLA-nonidentical family members (3%), or HLA-matched unrelated donors (12%) and for postgrafting immunosuppression with methotrexate and cyclosporine. We also examined the impact of chronic GVHD on survival and identified patients at low risk for chronic GVHD in whom immunosuppression might be stopped safely early after transplantation. Among 489 patients with either grade 0 or I acute GVHD, 33% developed chronic GVHD. Overall survival was 70%, and relapse-free survival was 63% at 8 years. Risk factors for chronic GVHD were found to include donor buffy coat infusions among patients given transplants for aplastic anemia (relative risk [RR] = 2.9, P = .05), patient-donor sex/parity combination (likelihood ratio test, P < .001), grade I acute GVHD (RR = 1.6, P = .003), and active cytomegalovirus infection (RR = 1.5, P = .05) before day 60. Among 45 patients aged <19 years who had male donors, only 1 developed chronic GVHD. This group had an overall survival rate of 65% and a relapse-free survival rate of 54% at 8 years post-transplantation-a result not better than that among the entire cohort. The lack of improvement in survival in the low-risk group was related to a high rate of relapse of the underlying diseases. Therefore, the development of de novo chronic GVHD does not have a negative impact on patient survival; the adverse effect from increased transplantation-related complications is offset by a lower relapse rate, the result of an allogeneic graft-versus-tumor effect.
Wagner
J L
JL
Clinical Research, Department of Medicine, University of Washington, Seattle, USA. john_wagner@lac.jci.tju.edu
Seidel
K
K
Boeckh
M
M
Storb
R
R
D000293:Adolescent; D000328:Adult; D016026:Bone Marrow Transplantation / Q000009:adverse effects* / Q000276:immunology / Q000401:mortality; D002648:Child; D002675:Child, Preschool; D016572:Cyclosporine / Q000008:administration & dosage*; D005260:Female; D006086:Graft vs Host Disease / Q000209:etiology / Q000276:immunology / Q000401:mortality / Q000517:prevention & control*; D006650:Histocompatibility Testing; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D007223:Infant; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage*; D012189:Retrospective Studies; D012307:Risk Factors; D016019:Survival Analysis; D014184:Transplantation, Homologous
D007166:Immunosuppressive Agents; D016572:Cyclosporine; D008727:Methotrexate